FDA Lays Out Roadmap to Clear Inspection Backlog as Biomanufacturing Booms

Biopharma manufacturing is booming, with companies opening new facilities across the globe to meet the demands of delivering medical products to patients in need. At the same time, the U.S. Food and Drug Administration (FDA) has a massive backlog of site inspections that has delayed some regulatory actions.